CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
15.3650
1.72%
Market Trading Hours* (UTC) Open now
Closes on Tuesday at 15:30

Mon - Fri: 07:00 - 15:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.1000
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025289 %
Charges from full value of position ($-4.80)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.025289%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003372 %
Charges from full value of position ($0.64)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003372%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.1
Currency GBP
Margin 5%
Stock exchange United Kingdom of Great Britain and Northern Ireland
Commission on trade 0%

*Information provided by Capital.com

Indivior PLC ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 15.6345
Open* 15.325
1-Year Change* 2.74%
Day's Range* 15.265 - 15.475
52 wk Range 11.25-20.20
Average Volume (10 days) 711.45K
Average Volume (3 months) 10.88M
Market Cap 1.63B
P/E Ratio -100.00K
Shares Outstanding 136.11M
Revenue 820.15M
EPS -1.37
Dividend (Yield %) N/A
Beta -0.34
Next Earnings Date Feb 22, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 15, 2024 15.6345 0.3795 2.49% 15.2550 15.8345 15.0355
Apr 12, 2024 15.5250 -0.7985 -4.89% 16.3235 16.3435 15.1055
Apr 11, 2024 16.1840 -0.0895 -0.55% 16.2735 16.4735 16.1240
Apr 10, 2024 16.2135 -0.0300 -0.18% 16.2435 16.6830 16.2035
Apr 9, 2024 16.3335 -0.1195 -0.73% 16.4530 16.7930 16.2235
Apr 8, 2024 16.8225 0.2095 1.26% 16.6130 16.9525 16.6130
Apr 5, 2024 16.9625 0.1300 0.77% 16.8325 17.1020 16.6630
Apr 4, 2024 17.1920 0.4395 2.62% 16.7525 17.4715 16.7325
Apr 3, 2024 17.0925 0.8790 5.42% 16.2135 17.2320 16.1635
Apr 2, 2024 16.5430 -0.2195 -1.31% 16.7625 16.8825 16.4530
Mar 28, 2024 17.0325 0.2300 1.37% 16.8025 17.1520 16.8025
Mar 27, 2024 16.9425 0.4990 3.03% 16.4435 16.9825 16.4135
Mar 26, 2024 16.4330 0.1295 0.79% 16.3035 16.5930 16.1340
Mar 25, 2024 16.4035 0.2400 1.48% 16.1635 16.5630 16.0935
Mar 22, 2024 16.3535 0.1400 0.86% 16.2135 16.4735 16.1040
Mar 21, 2024 16.4630 0.1995 1.23% 16.2635 16.7230 15.9640
Mar 20, 2024 15.8840 -0.2495 -1.55% 16.1335 16.6030 15.8840
Mar 19, 2024 16.5130 0.5490 3.44% 15.9640 16.5230 15.8840
Mar 18, 2024 16.1335 0.0895 0.56% 16.0440 16.2335 15.9040
Mar 15, 2024 16.0540 -0.0300 -0.19% 16.0840 16.5230 15.9640

Indivior PLC Events

Time (UTC) Country Event
Thursday, April 25, 2024

Time (UTC)

06:00

Country

GB

Event

Q1 2024 Indivior PLC Earnings Release
Q1 2024 Indivior PLC Earnings Release

Forecast

-

Previous

-

Time (UTC)

12:00

Country

GB

Event

Q1 2024 Indivior PLC Earnings Call
Q1 2024 Indivior PLC Earnings Call

Forecast

-

Previous

-
Friday, May 3, 2024

Time (UTC)

10:00

Country

GB

Event

Indivior PLC Annual Shareholders Meeting
Indivior PLC Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, May 9, 2024

Time (UTC)

11:00

Country

GB

Event

Indivior PLC Annual Shareholders Meeting
Indivior PLC Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, July 25, 2024

Time (UTC)

06:00

Country

GB

Event

Half Year 2024 Indivior PLC Earnings Release
Half Year 2024 Indivior PLC Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 901 791 647 785 1005
Revenue 901 791 647 785 1005
Cost of Revenue, Total 152 127 92 140 128
Gross Profit 749 664 555 645 877
Total Operating Expense 986 587 810 609 713
Selling/General/Admin. Expenses, Total 450 393 410 371 465
Research & Development 72 52 40 53 67
Depreciation / Amortization 11 13 17 19 13
Operating Income -85 204 -163 176 292
Interest Income (Expense), Net Non-Operating -4 -14 -8 4 -14
Net Income Before Taxes -95 190 -173 180 278
Net Income After Taxes -75 205 -148 134 273
Net Income Before Extra. Items -75 205 -148 134 273
Net Income -53 205 -148 134 275
Income Available to Common Excl. Extra. Items -75 205 -148 134 273
Income Available to Common Incl. Extra. Items -53 205 -148 134 275
Diluted Net Income -53 205 -148 134 275
Diluted Weighted Average Shares 139.012 154.228 146.573 151.072 150.228
Diluted EPS Excluding Extraordinary Items -0.53952 1.3292 -1.00974 0.887 1.81723
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 2.17967 1.60152 0.95516 1.01276 2.36973
Unusual Expense (Income) 303 2 251 26 40
Total Extraordinary Items 22 0 2
Dilution Adjustment 0
Other, Net -6 -2
Other Operating Expenses, Total -2
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 276 253 242 232 221
Revenue 276 253 242 232 221
Cost of Revenue, Total 50 39 44 40 38
Gross Profit 226 214 198 192 183
Total Operating Expense 215 196 500 176 158
Selling/General/Admin. Expenses, Total 125 117 134 113 106
Research & Development 32 27 29 20 14
Depreciation / Amortization 3
Unusual Expense (Income) 8 14 298 2 -5
Operating Income 61 57 -258 56 63
Interest Income (Expense), Net Non-Operating 4 3 3 -2 -5
Net Income Before Taxes 62 58 -255 54 58
Net Income After Taxes 39 44 -183 41 48
Net Income Before Extra. Items 39 44 -183 41 48
Net Income 39 44 -183 41 48
Income Available to Common Excl. Extra. Items 39 44 -183 41 48
Income Available to Common Incl. Extra. Items 39 44 -183 41 48
Diluted Net Income 39 44 -183 41 48
Diluted Weighted Average Shares 142.73 140.988 135.946 146.628 146.809
Diluted EPS Excluding Extraordinary Items 0.27324 0.31208 -1.34612 0.27962 0.32695
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.28025 0.42557 1.40497 0.29326 0.2929
Other Operating Expenses, Total 0 -5 1 2
Interest Expense (Income) - Net Operating -1
Other, Net -3 -2
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1259 1444 1187 1360 1329
Cash and Short Term Investments 893 1102 858 1060 924
Cash & Equivalents 774 1102 858 1060 924
Total Receivables, Net 225 215 186 204 318
Accounts Receivable - Trade, Net 220 202 179 192 269
Total Inventory 114 95 93 73 78
Prepaid Expenses 14 18 17 23 9
Total Assets 1769 1832 1531 1652 1547
Property/Plant/Equipment, Total - Net 85 95 103 107 57
Property/Plant/Equipment, Total - Gross 162 169 171 175 109
Accumulated Depreciation, Total -77 -74 -68 -68 -52
Intangibles, Net 70 82 62 72 84
Other Long Term Assets, Total 239 127 97 63 44
Total Current Liabilities 1019 804 599 742 818
Accounts Payable 36 137 20 39 47
Accrued Expenses 581 583 504 584 674
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 11 11 12 9 4
Other Current Liabilities, Total 391 73 63 110 93
Total Liabilities 1718 1629 1449 1443 1481
Total Long Term Debt 266 275 273 284 237
Long Term Debt 237 239 230 233 237
Other Liabilities, Total 433 550 577 417 426
Total Equity 51 203 82 209 66
Common Stock 68 70 73 73 73
Retained Earnings (Accumulated Deficit) 14 146 16 154 20
Other Equity, Total -39 -20 -13 -23 -32
Total Liabilities & Shareholders’ Equity 1769 1832 1531 1652 1547
Total Common Shares Outstanding 136.481 140.488 146.727 146.158 145.688
Note Receivable - Long Term 18 84 82 50 33
Additional Paid-In Capital 8 7 6 5 5
Capital Lease Obligations 29 36 43 51
Other Current Assets, Total 13 14 33
Short Term Investments 119
Long Term Investments 98
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1220 1094 1122 1259 1264
Cash and Short Term Investments 722 689 705 893 918
Cash & Equivalents 610 592 588 774 821
Total Receivables, Net 261 240 246 225 215
Accounts Receivable - Trade, Net 245 229 213 220 195
Total Inventory 142 131 123 114 106
Other Current Assets, Total 67 13 22 13 10
Total Assets 1852 1731 1755 1769 1671
Property/Plant/Equipment, Total - Net 85 89 88 85 80
Intangibles, Net 218 199 200 70 67
Note Receivable - Long Term 7 26 26 18 18
Other Long Term Assets, Total 270 230 221 239 125
Total Current Liabilities 1239 972 1043 1019 744
Accounts Payable 71 53 36 36 76
Accrued Expenses 643 636 621 581 557
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 11 12 11 11 10
Other Current Liabilities, Total 514 271 375 391 101
Total Liabilities 1876 1614 1683 1718 1444
Total Long Term Debt 266 269 268 266 266
Long Term Debt 236 236 236 237 237
Capital Lease Obligations 30 33 32 29 29
Other Liabilities, Total 371 373 372 433 434
Total Equity -24 117 72 51 227
Common Stock 69 69 69 68 69
Additional Paid-In Capital 11 9 9 8 8
Retained Earnings (Accumulated Deficit) -56 74 33 14 206
Other Equity, Total -48 -35 -39 -39 -56
Total Liabilities & Shareholders’ Equity 1852 1731 1755 1769 1671
Total Common Shares Outstanding 137.939 137.879 137.875 136.481 137.762
Short Term Investments 112 97 117 119 97
Prepaid Expenses 28 21 26 14 15
Long Term Investments 52 93 98 98 117
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -85 213 -156 178 292
Cash From Operating Activities -4 353 -193 151 303
Cash From Operating Activities 21 22 26 28 40
Non-Cash Items 1 -21 1 1 -34
Cash Taxes Paid 57 17 34 -18 16
Cash Interest Paid 24 18 20 17 25
Changes in Working Capital 59 139 -64 -56 5
Cash From Investing Activities -223 -14 -4 -2 -4
Capital Expenditures -6 -34 -4 -7 -41
Cash From Financing Activities -100 -94 -10 -13 -237
Total Cash Dividends Paid
Issuance (Retirement) of Debt, Net -12 6 -11 -13 -240
Foreign Exchange Effects -1 -1 5 0 -1
Net Change in Cash -328 244 -202 136 61
Issuance (Retirement) of Stock, Net -88 -100 1 0 3
Other Investing Cash Flow Items, Total -217 20 0 5 37
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 57 -85 173 117 54
Cash From Operating Activities -36 -4 14 -48 -75
Cash From Operating Activities 6 21 17 11 5
Non-Cash Items -17 1 -6 -9 -8
Cash Taxes Paid 21 57 35 21 2
Cash Interest Paid 10 24 18 13 9
Changes in Working Capital -82 59 -170 -167 -126
Cash From Investing Activities -127 -223 -221 -162 -149
Other Investing Cash Flow Items, Total 3 -217 -217 -160 -149
Cash From Financing Activities -22 -100 -72 -34 -2
Issuance (Retirement) of Stock, Net -9 -88 -64 -29 1
Issuance (Retirement) of Debt, Net -13 -12 -8 -5 -3
Net Change in Cash -186 -328 -281 -245 -228
Capital Expenditures -130 -6 -4 -2
Foreign Exchange Effects -1 -1 -2 -1 -2

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Indivior Company profile

About Indivior PLC

Indivior PLC is a United Kingdom-based pharmaceutical company. The Company is engaged in developing medicines to treat addiction and serious mental illnesses. It focuses to build a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and cooccurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as new therapies to address the needs of people suffering from alcohol, stimulant and cannabis use disorders. Its pipeline products include INDV-3000 - Selective Dopamine D3-receptor Antagonist, RBP-6000 - Buprenorphine XR injection, Buprenorphine/ Naloxone Sublingual Film, Buprenorphine/ Naloxone Sublingual Tablet and Buprenorphine Sublingual Tablet, among others. Its portfolio of products is available in more than 40 countries.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Indivior PLC revenues increased 22% to $791M. Net income totaled $205M vs. loss of $148M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Other operating income increase from $0K to $32M (income), Selling/General/Admin. Expense, decrease of 5% to $192M (expense).

Industry: Proprietary & Advanced Pharmaceuticals

234 Bath Road
SLOUGH
BERKSHIRE SL1 4EE
GB

Income Statement

  • Annual
  • Quarterly

News

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

People also watch

US100

17,688.30 Price
-0.340% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

62,180.95 Price
-1.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,371.66 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.50

ETH/USD

3,021.03 Price
-1.200% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading